Bac Vactory


A multidisciplinary research programme for the development of bacterial vaccines.

 

Introduction to the project

Bac Vactory is officially launched on 31 May 2017. The multidisciplinary research programme focuses on developing novel vaccine technology platforms in order to effectively prevent a set of (emerging) bacterial infections in animals and humans. 

Resistant bacteria make it difficult to fight infectious diseases in humans and animals. In fact, each year 25,000 people die as the result of antibiotic resistance in Europe alone. Antibiotic resistance is also a major problem in the livestock farming sector. The use of vaccines represents a cost-effective strategy to address these emerging, global human and animal health problems, and offers new ways to minimize the need for antibiotic treatment.

Project Aim

Bac Vactory combines extensive know-how from public and private partners on bacterial pathogenesis and innovative delivery systems with state-of-the-art technological advances on the identification of novel antigens and immuno-modulating compounds. Bac Vactory will specifically develop new vaccination technology that combats bacterial species responsible for major respiratory infectious diseases in both livestock and humans. This interdisciplinary ‘One Health’ approach will result in a technology center for accelerating the translation of knowledge into novel, effective, safe, and affordable bacterial vaccines for humans and animals. Programme Leader Prof. Jan Tommassen, Utrecht University: “An ounce of prevention is better than a pound of cure. By introducing new vaccines, we can reduce the use of antibiotics, and thereby reverse the development of antibiotics resistance.”

Bac Vactory will take a multi-angle approach that covers the entire technological vaccine development chain: from antigen discovery to vaccine formulation for selected pathogens causing similar diseases in humans and animals. By exploiting the vaccine development route in animals, clinical development of newly developed vaccine approaches for human use will be de-risked and accelerated.

Facts & Figures

  • Subsidy from STW-Perspectief (now: NWO-TTW Perspectief)
  • Total budget: 3 million Euros
  • Subsidy awarded: 2.1 million Euros
  • Public and private investment in Bac Vactory amounts over 0.9 million Euros
  • Project start: December 2016

Project partners

The Bac Vactory consortium consists of science and business partners: Utrecht University (Professor Dr Jan Tommassen, program leader), Eindhoven University of Technology (TU/e), Radboud University Medical Centre, Vrije Universiteit Amsterdam (VU), VU medical center, Wageningen Bioveterinary Research (WBVR), Abera Biosciences, GlaxoSmithKline (GSK), Pulike Bilogical Engineering Inc, Zoetis and Immuno Valley. 

Photo credit: Suzanne Blanchard